Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis
NCT ID: NCT01987167
Last Updated: 2017-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
25 participants
INTERVENTIONAL
2013-11-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
NCT02764697
Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis
NCT02769702
Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis
NCT03066869
Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
NCT03656692
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)
NCT02931175
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
-ACHTHAR
Subcutaneous ACTHAR 5 days of 80 IU and 10 Days of 40 IU
ACTHAR
Injectable Gel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACTHAR
Injectable Gel
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide informed consent
* age 18 or older
* can perform the above listed electrophysiologic diagnostic testing
* can perform high and low contrast visual acuity and visual field perimetry
Exclusion Criteria
* secondary progressive MS(SPMS)
* primary progressive MS (PPMS)
* undergoing treatment with medications approve for treatment of RRMS(except corticosteroids for a condition not involving central nervous system demyelination)
* prior diagnosis of systemic lupus erythematosis
* mixed connective tissue disease
* vasculitis
* sarcoidosis
* neuro-myelitis optica
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mallinckrodt
INDUSTRY
Neuro-Ophthalmologic Associates, PC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert C Sergott, M.D.
Role: PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neuro Ophthalmology
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Moster ML, Sergott RC, Leiby BE. Dalfampridine Treatment in Nonarteritic Anterior Ischemic Optic Neuropathy. J Neuroophthalmol. 2017 Sep;37(3):348-349. doi: 10.1097/WNO.0000000000000523. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACTHAR
Identifier Type: OTHER
Identifier Source: secondary_id
13-330
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.